DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDROXYUREA

« Back to Dashboard

Clinical Trials for Hydroxyurea

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00000586	Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	To assess the efficacy and safety of orally administered hydroxyurea in the treatment of painful crises in patients with sickle cell anemia.
NCT00000602	Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	To determine whether hydroxyurea prevents the onset of chronic end organ damage in young children with sickle cell anemia.
NCT00000623	Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	N/A	The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000623	Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)	Completed	Thalassemia Clinical Research Network	N/A	The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.
NCT00000623	Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)	Completed	New England Research Institutes	N/A	The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.

Clinical Trial Conditions for Hydroxyurea

Condition Name

Condition Name for Hydroxyurea
Intervention	Trials
Sickle Cell Disease	44
Sickle Cell Anemia	29
HIV Infections	17
Polycythemia Vera	17

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Hydroxyurea
Intervention	Trials
Anemia, Sickle Cell	83
Leukemia, Myeloid	29
Leukemia	29
Anemia	23

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Hydroxyurea

Trials by Country

Trials by Country for Hydroxyurea
Location	Trials
United States	656
Italy	61
Germany	36
France	33
Spain	26

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Hydroxyurea
Location	Trials
Illinois	43
New York	39
Texas	38
North Carolina	37
Maryland	35

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Hydroxyurea

Clinical Trial Phase

Clinical Trial Phase for Hydroxyurea
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	45
Phase 2/Phase 3	6

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Hydroxyurea
Clinical Trial Phase	Trials
Completed	93
Recruiting	52
Terminated	21

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Hydroxyurea

Sponsor Name

Sponsor Name for Hydroxyurea
Sponsor	Trials
National Cancer Institute (NCI)	24
National Heart, Lung, and Blood Institute (NHLBI)	21
Novartis Pharmaceuticals	16

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Hydroxyurea
Sponsor	Trials
Other	252
Industry	90
NIH	66

Export unavailable in trial.
Subscribe for complete access.